Nkarta, Inc. (NASDAQ:NKTX) Shares Sold by Bridgeway Capital Management LLC

Bridgeway Capital Management LLC reduced its position in shares of Nkarta, Inc. (NASDAQ:NKTX - Free Report) by 88.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,000 shares of the company's stock after selling 149,467 shares during the period. Bridgeway Capital Management LLC's holdings in Nkarta were worth $50,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. JPMorgan Chase & Co. lifted its holdings in Nkarta by 138.7% during the 4th quarter. JPMorgan Chase & Co. now owns 2,537,922 shares of the company's stock worth $6,319,000 after buying an additional 1,474,560 shares during the last quarter. Wasatch Advisors LP increased its position in shares of Nkarta by 37.4% during the fourth quarter. Wasatch Advisors LP now owns 2,520,909 shares of the company's stock worth $6,277,000 after purchasing an additional 686,229 shares in the last quarter. Alyeska Investment Group L.P. increased its position in shares of Nkarta by 23.0% during the fourth quarter. Alyeska Investment Group L.P. now owns 1,334,696 shares of the company's stock worth $3,323,000 after purchasing an additional 250,000 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Nkarta by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 1,181,357 shares of the company's stock worth $2,942,000 after purchasing an additional 10,331 shares in the last quarter. Finally, Affinity Asset Advisors LLC increased its position in shares of Nkarta by 23.1% during the fourth quarter. Affinity Asset Advisors LLC now owns 800,000 shares of the company's stock worth $1,992,000 after purchasing an additional 150,000 shares in the last quarter. 80.54% of the stock is currently owned by hedge funds and other institutional investors.

Nkarta Stock Up 1.2%

NKTX stock traded up $0.02 during trading on Friday, hitting $1.74. The company had a trading volume of 591,174 shares, compared to its average volume of 1,065,930. The firm has a market cap of $123.47 million, a PE ratio of -0.93 and a beta of 0.81. Nkarta, Inc. has a 1-year low of $1.31 and a 1-year high of $8.23. The firm has a 50-day moving average price of $1.79 and a 200-day moving average price of $2.21.

Nkarta (NASDAQ:NKTX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.01. Sell-side analysts anticipate that Nkarta, Inc. will post -1.7 earnings per share for the current year.

Analysts Set New Price Targets

NKTX has been the topic of a number of research analyst reports. HC Wainwright reiterated a "buy" rating and set a $18.00 target price on shares of Nkarta in a research report on Thursday, March 27th. William Blair reiterated a "market perform" rating on shares of Nkarta in a research report on Thursday. Needham & Company LLC cut their target price on Nkarta from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Thursday. Finally, Stifel Nicolaus cut their target price on Nkarta from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, March 27th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $14.67.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.